Medicare Part B suppliers may deliver the initial immunosuppressive drugs prescribed to a beneficiary after a transplant procedure to an address other than their home to ensure timely access to the medications at discharge, the Centers for Medicare & Medicaid Services announced last week in updated guidance. “In certain cases, a beneficiary who has received a transplant does not return home immediately after discharge,” the guidance states. “In order to ensure timely beneficiary access to prescribed immunosuppressive medications at the time of discharge, suppliers may deliver the initial prescriptions of a beneficiary’s immunosuppressive drugs to an alternate address, such as the transplant facility or alternative location where the beneficiary is temporarily staying, for example, temporary housing, instead of delivering the drugs to the patient’s home address.” AHA advocated for the policy change.

Related News Articles

Headline
The Government Accountability Office today named three new members to the Medicare Payment Advisory Commission through April 2023. They are: Wayne…
Headline
More than half of U.S. adults aged 70 and older have experienced a disruption in their medical care during the first month of social distancing for COVID-19,…
Headline
The AHA and other national hospital organizations today urged the Department of Health and Human Services and Centers for Medicare & Medicaid Services to…
Headline
The Medicare Hospital Insurance Trust Fund will have sufficient funds to pay full benefits until 2026, according to the latest annual report from the…
Headline
The Centers for Medicare & Medicaid Services recently granted Section 1135 Medicaid waivers for the COVID-19 emergency to Puerto Rico and the Commonwealth…
Headline
The Centers for Medicare & Medicaid Services clarified that the agency is waiving the Medicare coverage requirement for a three-day prior hospitalization…